Esperion Therapeutics Stock News

Here is how Esperion Therapeutics (ESPR) and TransMedics (TMDX) have performed compared to their sector so far this year.

At least two biotech stocks are triggering an options trading frenzy today, with Prometheus Biosciences Inc (NASDAQ:RXDX) and Esperion Therapeutics Inc (NASDAQ:ESPR) moving in opposite directions

Esperion Therapeutics reported its Q3 earnings with a beat on EPS and a slight miss on revenue. The company was able to report significant revenue growth and encouraging commercial trends. The highly

The consensus price target hints at a 32.5% upside potential for Esperion Therapeutics (ESPR). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earn

Esperion Therapeutics (ESPR) reports mixed third-quarter results, beating earnings estimates but missing out on sales.

Esperion Therapeutics, Inc. (NASDAQ:ESPR ) Q3 2022 Earnings Conference Call November 1, 2022 8:00 AM ET Company Participants Tiffany Aldrich - Associate Director, Corporate Communications Sheldon Koen

Esperion Therapeutics (ESPR) delivered earnings and revenue surprises of 12.90% and 4.30%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stoc

ANN ARBOR, Mich., Oct. 17, 2022 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced it will report third quarter 2022 financial results before the open of the U.S. financial markets on Tuesday

Esperion Therapeutics (ESPR) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further pric

Esperion Therapeutics (ESPR) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the

Esperion Therapeutics reported its Q2 earnings that revealed a beat on revenue, but a miss on EPS. However, the company announced that it has hit 100% MACE-4 accumulation. The company's mixed earnings

Esperion Therapeutics (ESPR) reports dismal second-quarter results, missing estimates for earnings and sales. However, shares rose on the back of ESPR's progress with its cardiovascular outcome study.

Start Time: 08:00 January 1, 0000 8:44 AM ET Esperion Therapeutics, Inc. (NASDAQ:ESPR ) Q2 2022 Earnings Conference Call August 02, 2022, 08:00 AM ET Company Participants Sheldon Koenig - President an

Esperion Therapeutics (ESPR) delivered earnings and revenue surprises of -10.53% and 2.62%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

ANN ARBOR, Mich., July 12, 2022 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR), today announced it will report second quarter 2022 financial results before the open of the U.S. financial markets on Tuesd